Aberrant GAS5 expression was reported in actively proliferating cancer cells including breast cancer [14], cervical cancer [15], colorectal cancer [16], gastric cancer [17], hepatocellular carcinoma [18], renal cell carcinoma [19], and glioma [20]. This evidence concerns the gene GAS5 and central nervous system cancer.